Pathophysiology and therapeutic strategies in the management of stroke: An update

Drugs of Today

Volumn 44, Issue 10, 2008, Pages 757-766

  Kumar, Anil ^a,b   Dogra, Samrita ^a  

^a PANJAB UNIVERSITY   (India)

^b PANJAB UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ALTEPLASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARUNDIC ACID; ASCORBIC ACID; CITICOLINE; CLOMETHIAZOLE; CLOPIDOGREL; DIAZEPAM; DIPYRIDAMOLE; DISUFENTON SODIUM; ETHYLENEGLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID BIS(2 OCTYLOXYETHYL) ESTER; FIBRINOLYTIC AGENT; HEPARIN; KR 31378; LAZAROID; LOW MOLECULAR WEIGHT HEPARIN; MUSCIMOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; SARUPLASE; STREPTOKINASE; TAK 044; TICLOPIDINE; TRAXOPRODIL; UNCLASSIFIED DRUG; WARFARIN;

ANTICOAGULANT THERAPY; CALCIUM INTAKE; CAROTID ENDARTERECTOMY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; GRANULOCYTOPENIA; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; LOW DRUG DOSE; NERVE CELL NECROSIS; NONHUMAN; PATHOPHYSIOLOGY; POTASSIUM INTAKE; PREVALENCE; REVIEW; RISK FACTOR; SEX DIFFERENCE; SODIUM INTAKE; STEM CELL TRANSPLANTATION;

ANIMALS; HUMANS; MODELS, THEORETICAL; NEUROPROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; THROMBOLYTIC THERAPY;

EID: 58949098027     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2008.44.10.1265487     Document Type: Review

References (48)

1. World Health Organization. Cerebrovascular Disorders: A Clinical and Research Classification, Vol. 43. World Health Organization: Geneva 1978.
2. Jones, T.H., Morawetz, R.B., Crowell, R.M. et al. Thresholds of focal ischemia in awake monkeys. J Neurosurg 1981, 54(6): 773-82.
3. Mohr, J.P., Choi, D.W., Grotta, J.C., Weir, B., Wolf, P.A. (Eds.). Stroke: Pathophysiology, Diagnosis and Management, Fourth Edition. Churchill Livingston: Philadelphia 2004.
4. Rosamond, W., Flegal, K., Friday, G. et al. Heart disease and stroke statistics - 2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007, 115(5): e69-171.
5. Stansbury, J.P., Jia, H., Williams, L.S., Vogel, W.B., Duncan, P.W. Ethnic disparities in stroke: Epidemiology, acute care, and postacute outcomes. Stroke 2005, 36(2): 374-87.
6. Challa, V. Atherosclerosis of the cervicocranial arteries. In: Toole, J.F. (Ed.). Cerebrovascular Disorders, 5th Edition. Lippincott Williams and Wilkins: Philadelphia 1999.
7. Fuster, V., Stein, B., Amboose, J.A., Badimon, L., Badimon, J.J., Chesebro, J.H. Atherosclerotic plaque rupture and thrombosis: Evolving concepts. Circulation 1990, 82(3 Suppl.): II47-59.
8. Garcia, J.H., Anderson, M.L. Circulatory disorders and their effects on the brain. In: Davis, R.L., Robertson, D.M. (Eds.). Textbook of Neuropathology, 3rd Edition. Williams & Wilkins: Baltimore 1997, 712-822.
9. Fonnum, F. Glutamate: A neurotransmitter in mammalian brain. J Neurochem 1984, 42(1): 1-11.
10. Garcia, J.H., Yoshida, Y., Chen, H. et al. Progression from ischemic injury to infarct following middle cerebral artery occlusion in the rat. Am J Pathol 1993, 142(2): 623-35.
11. Stark, K., Seubert, P., Lynch, G., Baudry, M. Proteolytic conversion of xanthine dehydrogenase to xanthine oxidase: Evidence against a role for calcium-activated protease (calpain). Biochem Biophys Res Commun 1989, 165(2): 858-64.
12. Chan, P.H., Fishman, R.A., Schmidley, J.W., Chen, S.F. Release of polyunsaturated fatty acids from phospholipids and alteration of brain membrane integrity by oxygen-derived free radicals. J Neurosci Res 1984, 12(4): 595-605.
13. Beckman, J.S., Koppenol, W.H. Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and the ugly. Am J Physiol 1996, 271(5, Pt. 1): C1424-37.
14. Miller, B., Sarantis, M., Traynelis, S.F., Attwell, D. Potentiation of NMDA receptor currents by arachidonic acid. Nature 1992, 355(6362): 722-5.
15. Ying, W., Han, S.K., Miller, J.W., Swanson, R.A. Acidosis potentiates oxidative neuronal death by multiple mechanisms. J Neurochem 1999, 73(4): 1549-56.
16. Hakim, A.M. Ischemic penumbra, the therapeutic window. Neurology 1998, 51(Suppl. 3): S44-6.
17. Heros, R. Stroke: Early pathophysiology and treatment. Stroke 1994, 25(9): 1877-81.
18. Chan, P.H. Mitochondrial dysfunction and oxidative stress as determinants of cell death/survival in stroke. Ann NY Acad Sci 2005, 1042: 203-9.
19. Waxman, E.A., Lynch, D.R. N-methyl D-aspartate receptor subtypes: Multiple roles in excitotoxicity and neurological disease. The Neuroscientist 2005, 11(1): 37-49.
20. Sugawara, T., Fujimura, M., Noshita, N. et al. Neuronal death/survival signaling pathways in cerebral ischemia. NeuroRx 2004, 1(1): 17-25.
21. Ha, H.C., Snyder, S.H. Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc Natl Acad Sci USA 1999, 96(24): 13978-82.
22. Yu, S.W., Wang, H., Poitras, M.F. et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis inducing factor. Science 2002, 297(5579): 259-63.
23. Park, E.M., Cho, S., Frys, K. et al. Interaction between inducible nitric oxide synthase and poly(ADP-ribose) polymerase in focal ischemic brain injury. Stroke 2004, 35(12): 2896-901.
24. Shi, Y.A. Structural view of mitochondria-mediated apoptosis. Nat Struct Biol 2001, 8(5): 394-401.
25. Merry, D.E., Korsmeyer, S.J. Bcl-2 gene family in the nervous system. Ann Rev Neurosci 1997, 20: 245-67.
26. Popa-Wagner, A., Carmichael, S.T., Kokaia, Z., Kessler, C., Walker, L.C. The response of the aged brain to stroke: Too much, too soon? Curr Neurovasc Res 2007, 4(3): 216-27.
27. Bath, P.M., Iddenden, R., Bath, F.J. Low-molecular-weight heparins and heparinoids in acute ischemic stroke: A meta-analysis of randomized controlled trials. Stroke 2000, 31(7): 1770-8.
28. Rourke, F., Dean, N., Akhtar, N., Shuaib, A. Current and future concepts in stroke prevention. CMAJ 2004, 170(7): 1123-33.
29. Albers, G.W., Amarenco, P., Easton, J.D., Sacco, R.L., Teal, P. Antithrombotic and thrombolytic therapy for ischemic stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126(3, Suppl.): 483S-512S.
30. Cheng, Y.D., Khoury, L.A., Zivin, J.A. Neuroprotection for ischemic stroke: Two decades of success and failure. NeuroRx 2004, 1(1): 36-45.
31. Chuang, D.M. Neuroprotective and neurotrophic actions of the mood stabilizer lithium: Can it be used to treat neurodegenerative diseases? Crit Rev Neurobiol 2004, 161(1-2): 83-90.
32. Planells-Cases, R., Montoliu, C., Humet, M., et al. Novel N-methyl D-aspartate (NMDA) receptor open channel blocker with in-vivo neuroprotectant activity. J Pharmacol Exp Ther 2002, 302(1): 163-73.
33. Choi Y., Kim, H.S., Shin, K.Y. et al. Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. Neuropsychopharmacology 2007, 32(11): 2393-404.
34. Irwing, E.A., Vinson, M., Rosin, C. et al. Identification of neuroprotective properties of anti-MAG antibody: A novel approach to treatment of stroke? J Cereb Blood Flow Metab 2005, 25(1): 98-107.
35. A receptors in the neuroprotective effect of theanine on focal cerebral ischemia in mice. J Pharmacol Sci 2007, 105(2): 211-4.
36. Lyden, P., Wahlgren, N.G. Mechanisms of action of neuroprotectants in stroke. J Stroke Cerebrovasc Dis 2000, 9(6 Pt. 2): 9-14.
37. Li, P.A., Kristián, T., He, Q.P., Siesjö, B.K. Cyclosporin A enhances survival, ameliorates brain damage, and prevents secondary mitochondrial dysfunction after a 30-minute period of transient cerebral ischemia. Exp Neurol 2000, 165(1): 153-63.
38. Clarkson, A.N., Sutherland, B.A., Appleton, I. The biology and pathology of hypoxia-ischemia: An update. Arch Immunol Ther Exp 2005, 53(3): 213-25.
39. Bazan, N.G. Neuroprotection D1 (NPD1): A DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathol 2005, 15(2): 159-66.
40. Sutherland, B.A., Shaw, O.M., Clarkson, A.N., Jackson, D.N., Sammut, I.A., Appleton, I. Neuroprotective effects of (-)- epigallocatechin gallate following hypoxia-ischemia-induced brain damage: A novel mechanism of action. FASEB J 2005, 19(2): 258-60.
41. Chascon, M.R., Jensen, M.B., Sattin, J.A., Zivin, J.A. Neuroprotection in cerebral ischemia: Emphasis on the SAINT trial. Curr Cardiol Rep 2008, 10(1): 37-42.
42. Diener, H.C., Schneider, D., Lampl, Y., Bornstein, N.M., Kozak, A., Rosenberg, G. DP-b99, a membrane-activated metal ion chelator, as neuroprotective therapy in ischemic stroke. Stroke 2008, 39(6): 1774-8.
43. Larsson, S.C., Virtanen, M.J., Mars, M., Mannisto, S., Pietinen, P., Albanes, D., Virtamo, J. Magnesium, calcium, potassium, and sodium intakes and risk of stroke in male smokers. Arch Intern Med 2008, 168(5): 459-65.
44. Pettigrew, L.C., Kasner, S.E., Gorman, M., Atkinson, R.P., Funakoshi Y., Ishibashi, H. Arundic Acid (ONO-2506) Stroke Study Group. Effect of arundic acid on serum S-100β in ischemic stroke. J Neurol Sci 2006, 251(1-2): 57-61.
45. Ohtani, R., Tomimoto, H., Wakita, H., Kitaguchi, H., Nakaji, K., Takahashi R. Expression of S100 protein and protective effect of arundic acid on the rat brain in chronic cerebral hypoperfusion. Brain Res 2007, 1135(1): 195-200.
46. Higgins, G. A., Ballard, T. M., Enderlin, M., Haman, M., Kemp, J.A. Evidence for improved performance in cognitive tasks following selective NR2B NMDA receptor antagonist pre-treatment in the rat. Psychopharmacology (Berl) 2005, 179(1): 85-98.
47. Fioravanti, M., Buckley, A.E. Citicoline (Cognizin) in the treatment of cognitive impairment. Clin Interv Aging 2006, 1(3): 247-51.
48. Savitz, S.I., Dinsmore, J.H., Wechsler, L.R., Rosenbaum, D.M., Caplan, L.R. Cell therapy for stroke. NeuroRx 2004, 1(4): 406-14.